POST Online Media Lite Edition


Orgenesis appoints Mario Philips to board

Christian Fernsby |
Germantown, Md., USA - Orgenesis, a cell and gene therapy company, announced that Mario Philips was appointed to Orgenesis’ board of directors.

Mr. Philips is Chief Executive Officer of PolyNeuroS, a drug company based in France that has developed a diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure neurodegenerative diseases such as ALS and Parkinson’s.

Mr. Philips also acts as strategic partner for the private equity fund, Archimed, and is Chairman of the Board for its portfolio company, Clean Biologics.

Prior to that, in 2017, he acted as Vice President and General Manager for Danaher Pall’s biotech business, with full P&L responsibility for a business unit.

Mr. Philips was promoted from the role of Vice President and General Manager of Pall to lead the Single-Use Technologies BU.

Mr. Philips joined ATMI in 1999 with ATMI’s acquisition of MST Analytics, Inc., serving as European Sales Manager for ATMI Analytical Systems.

In 2004, he was appointed as General Manager of ATMI Packaging, a role he held through 2010 when he was promoted to the position of Senior Vice President and General Manager, ATMI Life Sciences.

In that role, he was responsible for developing and executing all business strategies, including the introduction of new products and service solutions for the life sciences industry.

Mr. Philips also held several board member positions in the life sciences industry with Austar Life Sciences (China), Disposable Lab (France) and Artelis (Belgium).